Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...
Public interest has recently turned to the human eye and the Pfizer COVID-19 Vaccine. Two peer-reviewed papers have helped drive the latest debate. One Turkish cohort measured the cornea before and ...
Stream Connecticut News for free, 24/7, wherever you are. South African scientists say the Covid omicron variant significantly reduces antibody protection generated by Pfizer and BioNTech's vaccine, ...
Pfizer CEO Albert Bourla said that the main thing getting in the way of changing vaccine discussions in the U.S. is the ...
Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.
The fall COVID-19 vaccine season is starting slowly for Pfizer, with U.S. sales of its Comirnaty shots sinking 25% after federal regulators narrowed recommendations on who should get them. Approval of ...
Shares of COVID-19 vaccine makers Pfizer Inc (NYSE:PFE), BioNTech SE ADR (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) are trading lower Friday following a Washington Post report that Trump ...
Shares in Pfizer and Moderna fell 3.9% and 7.4%, respectively, Friday after a report that the Trump administration plans to link the deaths of 25 children to COVID vaccines. Trump health officials ...
Pfizer said Wednesday its Covid-19 vaccine was 100% effective in a study of adolescents ages 12 to 15, encouraging results that could clear the shots for use in middle school students before school ...